Key Takeaways
- • Almanac Health raised $10 million in a seed funding round led by F-Prime Capital, with participation from General Catalyst and Lightspeed Venture Partners, bringing total funding to nearly $12 million.
- • The clinical AI platform, founded by physician-researcher Cyril Zakka, MD, integrates evidence-based clinical decision support directly into existing EHR systems across medical specialties.
- • The company differentiates through peer-reviewed clinical validation, institutional governance controls, and elimination of pharmaceutical advertising influence in clinical recommendations.
- • General Catalyst led the company's earlier pre-seed round alongside Soma Capital, signaling investor confidence across multiple funding stages in the clinical AI sector.
- • The capital will accelerate deployment of specialist-grade clinical knowledge tools designed to improve clinician decision-making at the point of care.
Summary
Almanac Health, a Boston-based clinical artificial intelligence platform, has closed a $10 million seed round led by F-Prime Capital, with support from General Catalyst and Lightspeed Venture Partners. The funding brings the company's total capitalization to approximately $12 million since inception. The round represents sustained institutional backing for the company's evidence-based clinical decision support technology.
The platform was founded by Cyril Zakka, MD, a physician-researcher whose prior work at Stanford introduced retrieval-augmented generation techniques to clinical medicine. Almanac Health's core offering integrates specialist-grade medical knowledge into existing electronic health record systems, delivering evidence-based clinical decision support across multiple medical specialties. The company emphasizes clinically validated recommendations governed by institutional controls and explicitly free from pharmaceutical advertising influence—a distinction relevant to institutional buyers concerned with decision-support integrity.
The company's differentiation rests on peer-reviewed clinical validation of its AI models and integration with established healthcare infrastructure. Rather than building standalone applications, Almanac Health targets embedded functionality within EHR workflows, reducing adoption friction for health systems. This architectural approach positions the platform as complementary to existing clinical operations rather than disruptive.
General Catalyst's participation across both the pre-seed and seed rounds, alongside initial backing from Soma Capital, underscores sustained confidence in the clinical AI segment. The involvement of Lightspeed Venture Partners in this round adds another prominent venture firm to the syndicate. The capital deployment will focus on accelerating mission execution around bringing evidence-grounded AI tools to clinicians and health systems—a market segment that continues attracting significant venture attention as healthcare systems prioritize clinical safety and evidence-based outcomes.
The platform was founded by Cyril Zakka, MD, a physician-researcher whose prior work at Stanford introduced retrieval-augmented generation techniques to clinical medicine. Almanac Health's core offering integrates specialist-grade medical knowledge into existing electronic health record systems, delivering evidence-based clinical decision support across multiple medical specialties. The company emphasizes clinically validated recommendations governed by institutional controls and explicitly free from pharmaceutical advertising influence—a distinction relevant to institutional buyers concerned with decision-support integrity.
The company's differentiation rests on peer-reviewed clinical validation of its AI models and integration with established healthcare infrastructure. Rather than building standalone applications, Almanac Health targets embedded functionality within EHR workflows, reducing adoption friction for health systems. This architectural approach positions the platform as complementary to existing clinical operations rather than disruptive.
General Catalyst's participation across both the pre-seed and seed rounds, alongside initial backing from Soma Capital, underscores sustained confidence in the clinical AI segment. The involvement of Lightspeed Venture Partners in this round adds another prominent venture firm to the syndicate. The capital deployment will focus on accelerating mission execution around bringing evidence-grounded AI tools to clinicians and health systems—a market segment that continues attracting significant venture attention as healthcare systems prioritize clinical safety and evidence-based outcomes.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.